Last Updated on May 9, 2019 by Sultan Beardsley
A heads up to any of our team members who may be in ADMA Biologics (Nasdaq: ADMA). Today, after the market closed the ADMA’s stock, was halted pending news. I assume the news is regarding the approval of BIVIGAM’s prior approval supplement (PAS).
The last update we had was on January 7th when the company responded to a CRL. In the press release, ADMA stated it would be in communications with the FDA to resolve any concerns. This was reiterated in the latest earnings report “ongoing communications with the FDA to obtain approval of the BIVIGAM® drug substance Prior Approval Supplement (“PAS”) required to relaunch the product“.
I am excited about the news. This was what I have been waiting for and as many of you know was a core part of my investment thesis. Regardless of the outcome, it is important to be up and ready for what comes next tomorrow morning. Good luck to everyone and let’s get this bread!
I am/we are long ADMA.